PATENT CLAIM ANALYSIS

Application Number: 15879942
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "324000"]

Abstract:
A pharmaceutical combination comprising (a) an ALK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) at least one HDMA-2/p53 receptor inhibitor or a pharmaceutically acceptable salt, or at least one BRaf inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of cancer; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Claim (Index 3):
The method of treating cancer in a patient according to  claim 1 , wherein the cancer is neuroblastoma.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 86.0
- Lexical Diversity: 1.82353
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14777917', '14617079', '13699077', '15510414', '12139781']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7713723565709735
- 35 USC 102 Novelty (BERT): 0.5162940196285046
- Combined Prediction Score: 0.7458645228767267
- Mean Citation Score: 237.482686
- Max Citation Score: 247.35912
- Similarity Product: 152.22812382619858

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test